FAST-TRACK TIMELINES BY REMOVING HURDLES IN EARLY STAGE BIOLOGICS DEVELOPMENT THROUGH INNOVATIVE TECHNOLOGIES AND WORKFLOW SOLUTIONS.
EMPOWER THE DEVELOPMENT OF VITAL BIOLOGICS THAT CURE DISEASES.
Our mission drives us to do everything possible to develop vital biologics that cure diseases. We do that by enabling our customers to unlock workflow bottlenecks, by providing best-in-class products, by knowing the science behind our customers’ research, by providing first-class service and by being a trusted partner in finding solutions to research challenges.
ForteBio is a business unit of Molecular Devices LLC based in Fremont, CA. We offer products that span multiple technology vectors including analytical instrumentation and software, clone picking and imaging, and, automation and customization engineering solutions. Our customers perform crucial work in life sciences research across academic, government and industrial settings, including pharmaceutical research, development and manufacturing.
We develop and supply products for biomolecular analysis, including real-time analysis of biomolecular interactions (protein quantification and characterization of protein-protein interactions, etc.) in micro-volume sample sizes, providing information on affinity, kinetics, and concentration.
Our solutions for antibody discovery and cell line development provide dedicated, scalable, and easy-to-use products for establishing clonal populations. The systems feature a selection of options and models to address your specific research including multiple imaging modes, biology-specific pins, fluidics, and environmental control. These solutions combine intelligent imaging with analysis and automation to increase throughput, consistency, and provide image-based documentation.
Our Quality Management System is compliant to the requirements of ISO9001 International Standard that enhances our ability to design, develop, manufacture, deliver, maintain and support our products according to the highest quality standards continually and consistently.